



# MARKET RELEASE

15 June 2012

**Bioxyne Limited**

## SUSPENSION FROM OFFICIAL QUOTATION

The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company in relation to the results and data from its independent clinical research organisation which are continuing to be assessed.

Security Code:           BXN

Kimberley Brown  
Senior Adviser, Listings (Sydney)

**Ms Kimberley Brown  
Senior Adviser, Listing  
Australian Securities Exchange Limited  
SYDNEY**

**15 June, 2012**

## **Request for Voluntary Suspension**

Bioxyme Limited (the Company) (ASX Code: BXN) refers to its request for a trading halt on June 13<sup>th</sup> 2012.

The Company now requests that pursuant to ASX Listing Rule 17.2, that ASX grant an immediate suspension of the Company's Ordinary Shares (ASX:BXN) as it is continuing to assess the initial results and data received from its independent Clinical Research Organisation (CRO). The Company expects to be in a position to announce the results to the market by Friday 22<sup>nd</sup> June 2012.

The Company is not aware of any reason why the voluntary suspension should not be granted.

A handwritten signature in blue ink that reads 'Ashok Jairath'.

Yours faithfully  
Ashok Jairath  
Company Secretary



ABN: 97 084 464 193

Suite 1 A, Level 2  
802 Pacific Highway  
Gordon NSW 2072

P: +61 2 9844 5422  
F: +61 2 9844 5445



## About Bioxyne

Bioxyne Limited (ASX:BNE) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV, in Phase IIb clinical trials for Chronic Obstructive Pulmonary Disease (COPD), works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. The results of the Phase IIb clinical study into the safety and efficacy of HI-164OV are expected mid 2012. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit **[www.bioxyne.com](http://www.bioxyne.com)**